Acute Disseminated Demyelination Treatment Market Size

Acute Disseminated Demyelination Treatment Market size was over USD 10.48 Billion in 2023 and is likely to cross USD 19.28 Billion by the end of 2036, growing at more than 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of acute disseminated demyelination treatment is estimated at USD 10.93 Billion. The growth of this market can be attributed to the growing prevalence of acute disseminated demyelination disease worldwide with the rise in some recorded cases in recent times. As per our estimations, acute disseminated demyelination is expected to occur in approximately 0.8-2.0 cases per 100,000 individuals per year. Acute disseminated demyelination is more common in children and occurs more frequently in males than females.

Moreover, the rising prevalence of autoimmune diseases such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has increased the demand for acute disseminated demyelination treatment. The National Multiple Sclerosis Society reports that the prevalence of MS is increasing worldwide, affecting an estimated 2.8 million people worldwide. NMOSD is becoming more common, especially in Asia, with a prevalence of 0.05–10 per 100,000 people.